Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study

Background: This study aimed to describe the aberrations of DNA damage repair genes and other important driving genes in Chinese patients with metastatic castration-resistant prostate cancer (mCRPC) using circulating tumor (ctDNA) sequencing and to evaluate the associations between the clinical outcomes of multiple therapies and key genomic…

Read the full article here

Source: JNCCN
Categories: Hem/Onc News and Journals, Latest Headlines
Tags: , ,
Tweets with this article
Journal of the @NCCN
ONLINE FIRST: Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant #ProstateCancer: A Multicenter, Real-World Study: https://t.co/fhPFZvL1Gq #PCSM #cactc https://t.co/AHfQO9zfzu

Related Articles